Key facts
- This page summarizes Andrew R. Allen's Form 4 filing for Sierra Oncology, Inc..
- 6 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 01 Jul 2022, 16:38.
Andrew R. Allen - 01 Jul 2022 Form 4 Insider Report for Sierra Oncology, Inc.
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 01 Jul 2022
- Net transaction value
- -$90,750
- SEC form
- 4
- Accepted by SEC
- 01 Jul 2022, 16:38:35 UTC
- Prior SEC filing
- 20 Apr 2022
- Next SEC filing
- 19 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrew R. Allen; By: Mary Christina Thomson, Attorney-In-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Andrew R. Allen filed Form 4 for Sierra Oncology, Inc. on 01 Jul 2022.
Change
- Previous filing in this sequence was filed on 20 Apr 2022.
- Current net transaction value: -$90,750.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SRRA
transaction
Common Stock
Disposed to Issuer
- Transaction value
- $90,750
- Shares
- -1,650
- Change %
- -100%
- Price
- $55.00
- Shares after
- 0
- Date
- 01 Jul 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SRRA
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -750
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Jul 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 750
- Exercise price
- $26.40
- Footnotes
- F1, F2
SRRA
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -1,250
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Jul 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,250
- Exercise price
- $76.80
- Footnotes
- F3, F4
SRRA
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -625
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Jul 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 625
- Exercise price
- $130.80
- Footnotes
- F4, F5
SRRA
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -12,030
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Jul 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,030
- Exercise price
- $13.98
- Footnotes
- F2, F6
SRRA
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -6,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Jul 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,000
- Exercise price
- $18.11
- Footnotes
- F2, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Andrew R. Allen is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 7 footnotes
Footnote F1
The option fully vested on July 11, 2020.
Footnote F2
Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
Footnote F3
The option fully vested on November 10, 2018.
Footnote F4
Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger.
Footnote F5
The option fully vested on June 12, 2019.
Footnote F6
The option fully vested on June 9, 2021.
Footnote F7
The option fully vested on June 8, 2022.